Skip to main content

fCOI Main > Other Resources

Other Resources

NIH Training on Financial Conflicts of Interest

Responsibility of Applicants for Promoting Objectivity in Research, Major Changes to 1995 Regulations

Health and Human Services Department: Responsibility of Applicants for Promoting Objectivity in Research

NSF Conflict of Interest Policies

FDA Financial Disclosure by Clinical Investigators

COGR: Recognizing and Managing Personal Financial Conflicts of Interest

AAMC-AAU Report on Managing Conflicts of Interest

AAU Report on Individual and Institutional Financial Conflicts of Interest

JAMA Policy and Update

2009 COI Reporting Data (COI Administrator Access Only)

News Articles

Accountable and Transparent Financial Interests
The US government has changed how biomedical scientists disclose their financial interests. The revised rules are welcome, but Internet access to the identified conflicts should be a requirement.

Unfortunate Oversight
Scientists must remember that however irrelevant their involvement in industry might seem to them, others will see it differently only full disclosure will avert the taint of scandal.

Doctor Accused in Congress' Probe
An Emory University psychiatrist allegedly failed to report much of the income he received from firms whose drugs he was evaluating.

Researchers Fail to Reveal Full Drug Pay
A Harvard psychiatrist whose work has helped fuel an explosion in the use of powerful antipsychotic medicines in children, earned at least $1.6 million in consulting fees from drug makers, and failed to report much of this income to university officials.

Managing Financial Conflicts of Interest in Biomedical Research
As the nation's biomedical research agency, the National Institutes of Health (NIH) must ensure that the research it funds on the behalf of US taxpayers is scientifically rigorous and free of bias. Managing FCOI in biomedical and behavioral research, however, can prove to be a major challenge because of the complex relationships among government, academia, and industry.

Editor's Move Sparks Backlash
Bioethicists are forced to consider their purpose as leading practitioner joins controversial stem-cell company.

fCOI Main > Other Resources